The American Medical Association released a new report on Monday on pharmacy benefit managers. It explained that there is low competition among PBMs and high vertical integration with payers. The post AMA Report Details Low Competition in PBM Market appeared first on MedCity News.
About a third of small businesses discontinue their health insurance coverage from one year to the next, new research from JPMorganChase Institute shows. The post JPMorgan: How Small and Mid-Sized Businesses Make Healthcare Decisions appeared first on MedCity News.
While Google showcases AI’s ability to mimic human sentimentality, it misses the forest for the trees. The real innovation, the true potential of AI, lies not in replacing human expression but in enhancing human lives, particularly those of our rapidly aging population. The post Google’s Olympics Misstep and the Real AI Opportunity appeared first on…
Jessie Mazar squeezed the grab handle in her husband’s pickup and groaned as contractions struck her during the 90-minute drive from her home in rural northeastern California to the closest hospital with a maternity unit. She could have reached Plumas District Hospital, in Quincy, in just seven minutes. But it no longer delivers babies. Local…
Seaport Therapeutics’ Series B financing was one of the largest rounds of funding in our recap of biotech financing news, which spans startups developing drugs for neurological diseases, cancer, immunology, and more. The post Seaport Therapeutics Secures $225M for New Kind of Depression Drug appeared first on MedCity News.
Hooman Hakami, who has served as a senior executive at GE Healthcare and Medtronic, has been appointed CEO
In this episode, we’re joined by Carolee Lee, CEO and founder of Women’s Health Access Matters (WHAM), and Ash Shehata, KPMG U.S. sector leader for healthcare. The two discuss WHAM and KPMG’s new partnership that aims to advance women’s health research and investment. The post MedCity FemFwd: Inside WHAM & KPMG’s Women’s Health Partnership appeared…
Arrowhead Pharmaceuticals’ RNAi drug plozasiran, brand name Redemplo, is now the second FDA-approved therapy for familial chylomicronemia syndrome, an inherited lipid disorder. Beyond its claims of safety and dosing advantages, Arrowhead set a dramatically lower price for its first commercial product, which will compete against an Ionis Pharmaceuticals drug. The post With FDA Approval for…
Former President Trump and Vice President Harris have taken widely different stances and approaches on recognizing and addressing racial and ethnic disparities. These differences can be seen across areas of health care, including health coverage, reproductive and maternal health, and immigrant health and well-being and are likely to have important implications for future efforts to…
This Monitor highlights April KFF Tracking Poll findings on perceptions about measles and explores the unsubstantiated promotion of budesonide and clarithromycin as treatments. It also covers misrepresentations of syringe programs and how prompting strategies can boost the accuracy of AI chatbots on health questions.